Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inhibitor of apoptosis protein 1 (cIAP1)
- Target
- cIAP1
- Molecular classification
- Enzyme (specifically E3 ubiquitin ligase), Apoptosis regulator, Signal transduction adaptor
01
Overview
Inhibitor of apoptosis protein 1 (cIAP1) is a member of the IAP family, functioning as a negative regulator of apoptosis by directly inhibiting executioner caspases (such as caspase-3 and -7) and controlling cell death pathways. cIAP1 acts as an E3 ubiquitin ligase, modulating ubiquitin-dependent signaling that governs the activation of key pathways including NF-κB and MAPK. These processes affect not only cell survival and apoptosis, but also inflammation and innate immunity. cIAP1 is frequently overexpressed in cancers, contributing to tumor cell survival and therapeutic resistance, making it an important anti-cancer drug target; Smac-mimetic drugs that antagonize IAPs are in clinical development. The balance of cIAP1 activity is crucial to multiple cellular processes, and its deregulation is implicated in several disease settings including cancer, immune dysregulation, and metabolic stress.
- Other names
- Cellular inhibitor of apoptosis protein 1cIAP1
02
Mechanism of action
Drugs typically antagonize IAP function, primarily by displacing IAP–caspase interactions and/or inducing IAP protein degradation, thereby promoting apoptosis in target cells
03
Biological functions
Inhibition of apoptosis (cell death) by binding to and inhibiting caspasesRegulation of ubiquitin-dependent signaling pathways (including E3 ligase activity)Activation of the NF-κB and MAPK signaling pathwaysRegulation of inflammation and innate immune responseRegulation of cell proliferation and survival
04
Disease associations
Cancer (overexpression contributes to tumor cell survival, chemo-resistance, poor prognosis; therapeutic target for cancer therapy)InflammationImmune response and innate immunityOther: ER stress, β-cell survival in diabetes models
05
Safety considerations
Potential for excessive immune activation or unintended cell death (as IAP inhibition may deregulate apoptosis and inflammation)Resistance mechanisms in cancer, such as compensatory survival pathways or incomplete apoptosis induction
06
Interacting drugs
Smac-mimetics (small molecule IAP antagonists, currently under clinical evaluation for cancer; example agents include LCL161, birinapant, AT-406)
1 more in the full profile.
07
Biomarkers
Overexpression of cIAPs in tumors can serve as a biomarker for poor prognosis and potential patient selection for IAP-targeted therapies
Beyond the preview
Go deeper on Inhibitor of apoptosis protein 1 (cIAP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inhibitor of apoptosis protein 1 (cIAP1).